Novo Nordisk A/S, which now claims 25% of the global diabetes market, posted a 17% gain in sales to DKK 37.2 billion (€5 billion) in the 2012 first half year, powered by a 20% increase in local currency sales of synthetic insulins and an 82% rise in sales of Victoza (liraglutide), a glucagon-like peptide-1 analog for Type-2 diabetes.
